Your email has been successfully added to our mailing list.

×
0.00617283950617284 0.00617283950617284 0.0277469135802469 0.0185185185185185 -0.00308641975308649 -0.0216049382716049 -0.00617283950617284 -0.0154320987654322
Stock impact report

OncoMed Presents Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at the 2018 American Association for Cancer Research Annual Meeting

ONCOMED PHARMACEUTICALS (OMED) 
Last oncomed pharmaceuticals earnings: 11/1 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: oncomed.com/invest/index.cfm
Company Research Source: GlobeNewswire
REDWOOD CITY, Calif., April 18, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, presented preclinical data during the American Association for Cancer Research (AACR) Annual Meeting related to two of its therapeutic candidates, anti-TIGIT (OMP-313M32), currently in the Phase 1a portion of a Phase 1a/b study, and GITRL-Fc trimer (OMP-336B11), currently in a Phase 1a study. In addition, preclinical data was presented exploring the ability of OncoMed’s Wnt antagonist vantictumab (anti-FZD, OMP-18R5) to potentiate immune responses to checkpoint agents. TIGIT (T-cell immunoreceptor with Ig and ITIM domains) is an inhibitory checkpoint receptor that binds to PVR ligand, a protein broadly expressed on tumor cells and tumor-infiltrating cells, and, in doing so, blocks T-cell activation. OncoMed’s presentation (Abstract 5627) showed that anti-TIGIT treatment r Show less Read more
Impact Snapshot
Event Time:
OMED
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for OMED alerts
Opt-in for
OMED alerts

from News Quantified
Opt-in for
OMED alerts

from News Quantified